Last 129.75 GBp
Change Today -2.25 / -1.70%
Volume 118.7K
VEC On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 9:40 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

Open
131.50 GBp
Previous Close
132.00 GBp
Day High
131.75 GBp
Day Low
127.75 GBp
52 Week High
02/19/14 - 171.50 GBp
52 Week Low
11/20/13 - 101.00 GBp
Market Cap
522.2M
Average Volume 10 Days
351.5K
EPS TTM
-0.0071 GBp
Shares Outstanding
402.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc researches, develops, and commercialises novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company offers ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; Extraneal for the treatment of peritoneal dialysis; Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); and AirFlusal Forspiro for the treatment of asthma and COPD, as well as Asmasal and Asmabec for the treatment of asthma. Its full development stage products include VR315, VR506, and VR632 for the treatment of asthma. The company’s Phase III clinical stage products include NVA237 and QVA149 for the treatment of COPD; VR475 for the treatment severe adult asthma; and VR876 for the treatment of pulmonary hypertension. Its Phase II clinical stage products comprise VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; VR736 for the treatment severe influenza; and SB010 for the treatment of asthma and other respiratory diseases. The company’s Phase I clinical stage products include VR475 for the treatment severe adult asthma; VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases; and VR611 for the treatment of airways inflammatory and chronic cough diseases. The company also provides drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to enhance the performance of DPI products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides Gryohaler, lever-operated, open-inhale-close, AKITA Jet, APIXNEB, and FOX devices. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

281 Employees
Last Reported Date: 07/30/14
Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 674.0K GBP
Chief Financial Officer, Secretary and Direct...
Total Annual Compensation: 300.0K GBP
Chief Operations Officer, Director and Presid...
Total Annual Compensation: 482.0K GBP
Compensation as of Fiscal Year 2014.

vectura group plc (VEC) Key Developments

Vectura Group plc and Pfizer Limited Signs Exclusive Agreement

Vectura Group plc announced that alliance partner Novartis, has confirmed that Pfizer Limited has signed an exclusive agreement to commercialise Ultibro® Breezhaler® (indacaterol /glycopyrronium bromide) and Seebri® Breezhaler®(glycopyrronium bromide) in the United Kingdom.

Vectura Group plc Announces License Agreement for Asthma Monotherapy in US

Vectura Group plc has signed a US collaboration, development and license agreement for VR506, its clinical stage asthma monotherapy with an international pharmaceutical company. The agreement for VR506 is with Vectura's existing, undisclosed, US partner for VR315 (a combination therapy for asthma/COPD). Under the terms of this agreement, Vectura's partner will be responsible for the commercialisation and manufacture of the product together with clinical development. Vectura will provide support for the US development of VR506, for which it will receive an initial payment of $4 million and up to $8 million upon achievement of pre-determined development milestones. In addition, Vectura will receive a royalty from all VR506 US sales.

Vectura Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Vectura announced earnings results for the second quarter and six months ended June 30, 2014. For the quarter, sales were SEK 35 million and EBITDA was SEK 22 million against sales of SEK 34 million and EBITDA of SEK 22 million a year ago. For the six months, sales were SEK 61 million and EBITDA was SEK 35 million against sales of SEK 54 million and EBITDA of SEK 27 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 129.75 GBp -2.25

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Skyepharma PLC 307.25 GBp -11.75
View Industry Companies
 

Industry Analysis

VEC

Industry Average

Valuation VEC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 2.3x
Price/Cash Flow 112.4x
TEV/Sales 14.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit www.vectura.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.